Exane Derivatives’s Sunrun RUN Stock Holding History

Exane Derivatives’s Portfolio RUN Stock Details RUN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,612	Closed	-$79.3K	–	892
2022 Q1	$79.3K	Buy	+2,612	New	+$72.9K	0.02%	501
2021 Q4	–	Sell	-2,778	Closed	-$122K	–	949
2021 Q3	$122K	Sell	2,778 -17	-0.6%	-$811	0.03%	497
2021 Q2	$149K	Sell	2,795 -9,655	-78%	-$466K	0.03%	482
2021 Q1	$753K	Buy	+12,450	New	+$865K	0.22%	104

Other funds holding RUN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $44.4B AUM 36.05% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Greenvale Capital London, United Kingdom $916M AUM 32.73% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

Exane Derivatives's RUN Position: Q2 2022 in Review

Exane Derivatives sold out of Sunrun (RUN) in Q2 2022, closing a stake of 2,612 shares — an estimated $79.3K sold.

Exane Derivatives first reported a position in RUN in Q1 2021 and held it in 4 quarters. The position peaked at $753K in Q1 2021. 413 funds tracked by Wall St. Rank hold RUN as of Q2 2022.

Exane Derivatives reported no remaining Sunrun position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 2,612 Sunrun shares in Q2 2022, an estimated $79.3K.
Exane Derivatives first reported a position in Sunrun in Q1 2021 and held it in 4 quarters.
Exane Derivatives's Sunrun position peaked at $753K in Q1 2021.
413 funds tracked by Wall St. Rank held Sunrun as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.